Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
ConclusionsSequential epirubicin and docetaxel monotherapy caused profound redistribution of smaller subclones in primary breast cancer, while early truncal mutations and major subclones generally persisted through treatment.Trial registrationClinicalTrials.gov,NCT00496795, registered on July 4, 2007.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Genetics | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Taxotere